Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
61 results about "Tumor immunosuppression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer-induced immunosuppression is a survival/defense mechanism used by cancer cells to escape elimination by the immune system. Immunosuppression is the act of inhibiting or dampening the functional activity of immune cells.
Recombinant lentivirus and application thereof
ActiveCN106749675ASignificant in vivo and in vitro amplificationSignificant tumor killing effectMammal material medical ingredientsImmunoglobulinsAbnormal tissue growthMicro environment
The invention relates to the field of tumor cellular immunotherapy, and in particular relates to a recombinant lentivirus and application thereof. The recombinant lentivirus comprises a chimeric antigen receptor, wherein the chimeric antigen receptor mainly comprises signal peptide, an antigen recognition domain, a transmembrane domain, an intracellular co-stimulation signal transduction domain and a CD3 zeta signal transduction domain which are serially connected; the intracellular co-stimulation signal transduction domain mainly comprises a human TLR2 (Toll Like Receptor 2) intracellular domain. A GPC3 CAT T (Glypican 3 CAT T) cell prepared from the recombinant lentivirus has an intense cell killing effect on liver cancer cells, a Th1 cell factor can be highly expressed, a tumor killing effect caused by non-CAR T (Chimeric Antigen Receptor T) cell can be stimulated to the maximum extent, escape and potential reoccurrence risk of GPC 3-tumor cells can be effectively prevented, the tumor cells can be killed by T cells expressing the chimeric antigen receptor, normal tissue can be slightly damaged, a tumor immunosuppression micro environment can be broken through, and thus a relatively good treatment effect on solid tumor can be achieved.
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD
Construction method and application of lentiviral vector for expressing TGF-beta antibody as well as construction method and application of CAR-T cell
InactiveCN108949828AAchieve new breakthroughs in immunotherapySuppress immune responseGenetically modified cellsMammal material medical ingredientsAbnormal tissue growthAntigen
The invention discloses a construction method and an application of a lentiviral vector for expressing a TGF-beta antibody as well as a construction method and an application of a CAR-T cell based onthe problem that immunosuppression molecules and suppressor cells are the biggest barriers in the treatment of solid tumors in a tumor immunosuppression microenvironment, relating to the technical field of tumor immunotherapy. The invention discloses the lentiviral vector which carries a CAR gene of a solid tumor specific antigen target spot of the TGF-beta antibody as well as the CAR-T cell for expressing the solid tumor specific antigen target spot of the TGF-beta antibody. The construction methods and the application have the beneficial effects that the targeting effect on the tumor cells is realized, the suppressor cells in the tumor microenvironment are reduced, the solid tumors are killed to an extreme extend, and the new breakthrough on the immunotherapy of the solid tumors is realized.
Owner:安徽古一生物科技有限公司
39-desmethoxy-39-methyl derivatives of rapamycin
InactiveUS7897608B2Low in DOEliminate side effectsBiocideSenses disorderImmunologic disordersFibrosis
The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39 -methylrapamycin derivatives in the treatment of cancer and / or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.
Owner:BIOTICA TECH
Tumor cell vaccine simultaneously secreting PD-1 neutralizing antibody and GM-CSF factor and preparation method thereof
InactiveCN105031630AGood anti-tumor effectLifting of immunosuppressionAntibody ingredientsImmunological disordersTreatment fieldTherapeutic effect
The invention discloses the field of tumor cellular immunotherapy and particularly relates to a tumor cell vaccine which is modified by a PD-1 neutralizing antibody with combination of a GM-CSF factor and a preparation method thereof. In the invention, tumor cellular vaccine therapy is creatively combined with antibody therapy which relieves tumor immune-suppression, so that the prepared tumor cell vaccine simultaneously secreting the PD-1 neutralizing antibody and the GM-CSF factor can not only relieve the immune-suppression status of a tumor micro-environment but also enhance an antitumor immune reaction. The tumor cell vaccine is good in antitumor treatment effect, is excellent in development value and provides a new approach of tumor cellular immunotherapy.
Owner:SICHUAN UNIV
Tumor antigen loaded polydopamine nanoparticles, and preparation method and application thereof
ActiveCN111346236AGood biocompatibilityThe preparation method is simple and gentlePowder deliveryCancer antigen ingredientsAdjuvantTumor antigen
The invention relates to a tumor antigen loaded polydopamine nanoparticle, and a preparation method and an application thereof. The tumor antigen loaded polydopamine nanoparticle is prepared by covalently connecting a tumor antigen to the surface of a polydopamine nanoparticle through Michael addition and Schiff base reaction, wherein the tumor antigen comprises, but is not limited to, one or moreselected from the group consisting of a specific tumor antigen peptide fragment, a tumor cell lysate, a specific tumor antigen DNA fragment and an adjuvant CpG. The tumor antigen loaded polydopaminenanoparticle prepared by using the method provided by the invention has good biocompatibility, can effectively activate in-vivo anti-tumor immunity, significantly inhibits the growth of tumor cells, can improve the tumor immunosuppressive microenvironment, further enhances the anti-tumor activity of the human body, can be used for immune treatment of tumors, and is simple and pollution-free in preparation method.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Triptolide and chinese brake herb general flavone combined medicinal composition and preparation and application thereof
InactiveCN102793729ALow toxicityImprove immunosuppressionOrganic active ingredientsAntipyreticMedicinal herbsAntiinflammatory drug
The invention belongs to the field of medicines and discloses a triptolide and chinese brake herb general flavone combined medicinal composition and preparation and application thereof. The medicinal composition is prepared by uniformly mixing 1 weight part of triptolide and 10<-3> to 10<5> weight part of chinese brake herb general flavone. The chinese brake herb general flavone is prepared from chinese brake herb through ethanol solution extraction, organic solvent distribution, and macroporous resin and polyamide column refining. The medicinal composition can be applied to preparation of medicines for treating rheumatoid arthritis, anti-tumor medicines, immunosuppression medicines, and anti-inflammatory medicines.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Group of substituted benzoheterocycle amine derivatives and preparation method and related application thereof as IMPDH (inosine monophosphate dehydrogenase) inhibitor
ActiveCN103992310AOrganic active ingredientsOrganic chemistryInosine-5′-monophosphate dehydrogenaseScreening study
The invention discloses a group of substituted benzoheterocycle amine derivatives and a preparation method and related application thereof as an IMPDH (inosine monophosphate dehydrogenase) inhibitor. The IMPDH inhibitor has good application prospects in virus resistance, immunosuppression, tumor resistance, bacterium resistance, parasite resistance and the like. In the invention, a new-structure IMPDH inhibitor shown by the formula (I) is obtained through the design, synthesis and activity screening study on an active compound targeting IMPDH, and a foundation is laid for the development and application of the compounds as the medicines and medicinal compositions thereof with related effects such as virus resistance, tumor resistance, immunosuppression and the like.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Black garlic extract and application thereof in preventing and curing breast cancer
InactiveCN105596674AGrowth inhibitionReduce vitalityNatural extract food ingredientsAntineoplastic agentsT47d cellCancer cell
The invention belongs to the technical field of food, and discloses a black garlic extract and application thereof in preventing and curing breast cancer. It is proved by the cell test that the black garlic extract inhibits growth of breast cancer MD231 cells and T47D cells in a concentration-dependent and time-dependent manner, so that the adhesiveness among cancer cells is enhanced, and the vigor of the cancer cells is reduced; besides, it is proved by the animal test that the black garlic extract can inhibit growth of nude mouse MCF-7 transplanted tumor remarkably, the gross tumor volume is reduced, the thymus index and the spleen index are increased, tumor immunosuppression is avoided, and the black garlic extract has the immunological enhancement effect. Therefore, the black garlic extract can be used for preventing and curing breast cancer, is rich in source and pure-natural, and has important development and application prospects.
Owner:广东益生康生物科技有限公司
Pharmaceutical applications of hq-091212
InactiveCN102258525AImprove bioavailabilityNo cross resistanceOrganic active ingredientsImmunological disordersMammalian tissueDosage form
The present invention relates to the application of the diterpene lactone compound (HQ-091212) represented by formula (1) in the preparation of antitumor drugs and immunosuppressants. The pharmaceutical composition of the present invention can be made into tissues and organs beneficial to mammals The dosage form for absorption and utilization has good application prospects in the treatment of proliferative diseases such as tumors and immunosuppression.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
Composition and immune cells for enhancing T lymphocyte immunity and application
ActiveCN110694061ARaise the ratioResolve inhibitionCancer antigen ingredientsAntineoplastic agentsWhite blood cellReceptor
The invention discloses a composition and immune cells for enhancing T lymphocyte immunity and application. The composition of the present invention comprises the following components (a) to (d): (a)interleukin-15, a mutant thereof or a functional fragment thereof, or an encoding nucleic acid thereof; (b) interleukin-15 receptor alpha, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; (c) interleukin-12, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; and (d) a PD1-CD80 fusion protein, a mutant or a functional fragment thereof, oran encoding nucleic acid thereof. The composition, the immune cells and the method for improving the properties of the T lymphocytes can all excite stronger immune response, and induce tumor specificCD4 and CD8T cells in a higher proportion, so that the defects of tumor immunosuppression and non-ideal clinical effect which are difficult to solve by a single tumor treatment means are expected to be overcome.
Owner:启辰生生物科技(珠海)有限公司
Method and system for improving size-based product recommendations using aggregated review data
ActiveCN106459224ARecognition specificityImprove targetingPolypeptide with localisation/targeting motifImmunoglobulin superfamilyProduct selectionHuman–computer interaction
A recommendation system collects and aggregates customer feedback information to improve recommendations of wearable items to a consumer as well as provide manufacturers feedback related to their products. For example, the recommendation system may provide a user of a product selection system with an automated recommendation of a recommended size for a selected wearable item. After the user has purchased the selected wearable item, the system may present the user with a prompt to provide feedback relating to the item and / or a quality of the automated recommendation. When the system receives the feedback from the user and other consumers, the system may aggregate the user feedback to improve an aspect of the recommended size of the selected wearable item in the future. Additionally, the user's feedback, or a collection of aggregated user feedback, can be provided to the manufacturer of the purchased item.
Owner:BLUE ELEGANT BIOTECH CO LTD
Aspirin derivative as well as preparation method, medicine and application thereof
ActiveCN111349108AEasily hydrolyzedImprove metabolic behaviorOrganic active ingredientsAntipyreticUltraviolet lightsTumor therapy
The invention provides an aspirin derivative. The aspirin derivative has a structure as shown in a formula (I) which is described in the specification. The aspirin prodrug with the structure has the capability of sensitively releasing aspirin or salicylic acid under the stimulation of active oxygen or ultraviolet light; furthermore, the sensitive aspirin prodrug with the structure is combined to aspecific polymer carrier; an obtained bonding drug can be enriched to tumor tissues and rapidly release the drug, so that the bonding drug has a wide development prospect in the fields of reducing inflammation of the tumor tissues, improving a tumor immunosuppression microenvironment and inhibiting tumor growth. The aspirin polymer prodrug provided by the invention can be enriched at a tumor or inflammatory site, improve the in-vivo metabolic pathway of aspirin, and can effectively solve the problems of short action time and poor curative effect of micromolecular aspirin. Moreover, the preparation method provided by the invention is simple, wide in raw material source and capable of realizing batch production and industrialization.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Calcium carbonate based compound micro particles and preparation and application thereof
ActiveCN111888337AUniform particle sizeGood dispersionOrganic active ingredientsEnergy modified materialsAntitumor immunityTumor reduction
The invention relates to calcium carbonate based compound micro particles and preparation and application thereof. The calcium carbonate based compound micro particles disclosed by the invention comprise calcium carbonate and a macromolecule stable layer, wherein the macromolecule stable layer comprises amphipathic molecules and / or hydrophilic molecules. The invention further discloses applicationof the calcium carbonate based compound micro particles to preparation of one or more of an adjuvant, a chemotherapy enhancing adjuvant, a radiotherapy enhancing adjuvant and a radiofrequency ablation treatment adjuvant for tumor immnuotherapy. The calcium carbonate based compound micro particles disclosed by the invention have an excellent effect of regulating a tumor slight acid environment, can reduce content of immunosuppressive cells in tumor, increase content of immune cells capable of killing the tumor and promote polarization of tumor-associated macrophages from the M2 type to the M1type, effectively turns the tumor immunosuppression micro environment, activate antitumor immunity, and can enhance a suppression effect of various treatment means of immunotherapy, chemotherapy, radiotherapy, radiofrequency ablation treatment and the like on tumor growth.
Owner:SUZHOU UNIV
Anti-tigit antibodies and uses thereof
ActiveUS20210087268A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigen Binding FragmentTyrosine
Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
Owner:YUHAN
Novel PD-1 tumor immunosuppressant and drug preparation method thereof
InactiveCN108498796AImprove antigen phagocytosisRapid responseHeavy metal active ingredientsOrganic active ingredientsApoptosisT cell
The invention relates to the technical field of drug inhibitors, in particular to a novel PD-1 tumor immunosuppressant and a drug preparation method thereof. The immunosuppressant is prepared from byweight, 30-45 parts of PD-1 monoclonal antibody, 2-6 parts of alkaloid, 4-7 parts of antibiotic, 3-9 parts of alkylating agent, 1-5 parts of platinum agent and 5-9 parts of metabolic antagonist; the alkaloid consists of one or more of paclitaxel, vincristine and docetaxel; the antibiotic consists of one or more of epirubicin, idarubicin and mitomycin; the alkylating agent is one or two of ifosfamide and dacarbazine; the platinum agent is one or two of cisplatin and oxaliplatin; the metabolic antagonist is one or more of gemcitabine, cytarabine and tegafur. The immunosuppressant can block the interaction between PD-L1 molecules expressed on tumor cells and receptors on activated T cells, inhibit the apoptosis of the activated T cells and improve the killing capability of the tumor cells.
Owner:HENAN TIANSHENG TAIFENG PHARM TECH CO LTD
Biomarker analysis method based on multiple immunohistochemical technologies and application thereof
ActiveCN113450877AReduce cumbersome workEfficient analysisBiostatisticsInstrumentsCell phenotypeScientific study
The invention provides a biomarker analysis method based on multiple immunohistochemical technologies and application thereof. According to the biomarker analysis method, histomorphology, cell phenotype and corresponding space coordinate information of a tumor tissue sample of an image recognition system are utilized, and the tumor immune microenvironment is automatically analyzed through two biomarkers including double-positive cell scoring and tumor-immunosuppression relative distance ratio. The invention also provides a device and equipment for implementing the method, and a corresponding computer readable medium. By means of the method, the space connection state of the tumor immune microenvironment can be more accurately and efficiently represented, the tumor immune microenvironment related indexes can more effectively evaluate the immune treatment effect, and the requirements for tumor immune microenvironment analysis through multiple immunohistochemical technologies in clinical pathological work and scientific research are met.
Owner:深圳裕泰抗原科技有限公司
Fusion protein for EGFR+ tumors and application thereof
InactiveCN109734811AMeeting the need for immunotherapyEnhance immune responsePeptide/protein ingredientsMacromolecular non-active ingredientsFc(alpha) receptorSignalling pathways
The invention relates to a multifunctional fusion protein for EGFR+ tumor cells. The protein comprises an antibody function domain which specifically recognizes tumor antigen EGFR, a SIRP alpha extracellular function domain which blocks a tumor immunosuppressive antigen CD47 signal, a high affinity IgG1Fc which binds to an Fc receptor and a non-functional amino acid fragment for being connected with the function domains; the invention also relates to the preparation and application of the above fusion protein. The recombinant fusion protein both can recognize EGFR-positive tumor cells and block a CD47 immunosuppressive signal pathway, a high-affinity Fc portion can enhance the immune response of immune cells to tumors, and the protein has good clinical prospects and wide range of application.
Owner:上海科弈药业科技有限公司
Calcium carbonate poly(lactic acid-glycolic acid) composite particle and preparation and application thereof
ActiveCN111888336AImprove loading efficiencyImplement responsive releaseOrganic active ingredientsInorganic non-active ingredientsPolyethylene glycolTumor chemotherapy
The present invention relates to a calcium carbonate poly(lactic acid-glycolic acid) composite particle and a preparation and an application thereof. The calcium carbonate poly(lactic acid-glycolic acid) composite particle is prepared by using alkyl-modified NLG919, polylactic acid-glycolic acid and polylactic acid-glycolic acid-polyethylene glycol as a shell layer, and calcium carbonate and doxorubicin as a core layer. The present invention also discloses the application of the calcium carbonate poly(lactic acid-glycolic acid) composite particle in preparation of drugs for tumor chemotherapyor combined tumor chemotherapy and immune therapy. The composite particle can be used as a drug carrier, has good drug loading efficiency and tumor enrichment ability, realizes co-loading of a chemotherapy drug DOX and an IDO inhibitor aNLG919, can also effectively release the chemotherapy drug doxorubicin and also inhibit IDO immunosuppressive pathways, effectively reverses tumor immunosuppressive microenvironment, activates tumor immunity, inhibits tumor growth, and realizes tumor chemotherapy or combined chemotherapy and immune therapy.
Owner:SUZHOU UNIV
Composition for removing tumor immunosuppression and application thereof
ActiveCN110732021ALifting of immunosuppressionDisinhibitionPeptide/protein ingredientsGenetically modified cellsReceptorCD80
The invention discloses a composition for removing tumor immunosuppression and application thereof. The composition provided by the invention comprises following (a) to (e) components or coded nucleicacid thereof: (a) IL-15, a mutant thereof or functional fragments thereof; (b) an IL-15 receptor alpha, a mutant thereof or functional fragments thereof; (c) IL-12, a mutant thereof or functional fragments thereof; (d) TGF-beta regulatory peptide, a mutant thereof or functional fragments thereof; and (e) PD1-CD80 fusion protein, a mutant thereof or functional fragments thereof. According to the composition provided by the invention, the immune response of T lymphocytes can be improved synergistically.
Owner:BEIJING TRICISIONBIO THERAPEUTICS INC
Antibody with double mic binding activity and application thereof
ActiveCN112574311BHigh affinityImprove adsorption capacityOther chemical processesBiological material analysisNkg2d ligandsAntiendomysial antibodies
Owner:GUANGZHOU KONCEN BIOSCI
Anti-placenta-like chondroitin sulfate chimeric antigen receptor and applications thereof
InactiveCN106977607ARecognition specificityImprove targetingPolypeptide with localisation/targeting motifImmunoglobulin superfamilyTreatment effectAntigen receptors
The present invention relates to the field of cellular immunotherapy for tumors, particularly to an anti-placenta-like chondroitin sulfate (pl-CS) chimeric antigen receptor and applications thereof, wherein the chimeric antigen receptor is mainly formed by linking an anti-pl-CS antigen recognition region, a hinge region, a transmembrane domain and an intracellular region in series, the anti-pl-CS antigen recognition region is plasmodium protein VAR2CSA, the partial peptide fragment of the plasmodium protein VAR2CSA, or any one of pl-CS antibodies, and the partial peptide fragment of the plasmodium protein VAR2CSA is the peptide fragment having an amino acid number of greater than 500 in the plasmodium protein VAR2CSA. According to the present invention, the T cells expressing the chimeric antigen receptor can kill the tumor cells to the greatest extent, causes little damage to normal tissues, and can break through tumor immunosuppressive microenvironments, such that the god treatment effects can be provided for solid tumors, and almost various types of tumors can be treated.
Owner:GUANGZHOU CAS LAMVAC BIOTECH CO LTD
A kind of recombinant lentivirus and its application
ActiveCN106749675BActivate tumor immune effectEfficient tumor recognition killing effectMammal material medical ingredientsBlood/immune system cellsCancer cellAntigen receptors
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD
Application of TIGIT immunoadhesin in products for regulating tumor immunity and angiogenesis
ActiveCN112190689AHigh clinical application prospectsExpand the scope ofPeptide/protein ingredientsImmunological disordersBlood vessel injuryTIGIT
The invention relates to the technical field of biomedical engineering, and discloses a new application of TIGIT immunoadhesin in products for regulating tumor immunity and angiogenesis, and the experimental results showed that the TIGIT immunoadhesin can effectively enhance the ability of immune cells to kill and recognize tumor cells, enhance the growth inhibition of immune cells on tumor tissues, improve immunosuppression signals in tumor tissues, break the tumor immunosuppression microenvironment, meanwhile, improve the tumor tissue oxygen deficit condition, increase blood flow supply is increased and change the tumor growth environment , so that tumor cells are hammered in two ways. On the other hand, the TIGIT immunoadhesin can stimulate angiogenesis and enhance the healing of new tissues, so that a certain direction is provided for the treatment of vascular injury diseases, and the clinical application prospect and range of the TIGIT immunoadhesin are expanded.
Owner:PHARCHOICE THERAPEUTICS INC
Small molecule conjugates specifically activated in tumor microenviroment for targeting and use thereof
ActiveUS20170266308A1Low toxicityAvoid toxicityOrganic active ingredientsPharmaceutical non-active ingredientsChemotherapeutic drugsWilms' tumor
Provided is an anticancer compound including a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.
Owner:YAFEI (SHANGHAI) BIOLOG MEDICINE SCI & TECH CO LTD
Application of TMUB1 protein in preparation of tumor immunosuppressive molecular detection agent
ActiveCN112462072ALower levelBlock immune escapeOrganic active ingredientsMicrobiological testing/measurementImmune escapeBiochemistry
The invention discloses an application of a TMUB1 protein in preparation of a tumor immunosuppressive molecule detection agent, and provides a method for detecting the expression level of the TMUB1 protein and an application of a TMUB1 protein inhibitor in inhibition of tumor immunosuppressive molecules at the same time, in the invention, the TMUB1 with low expression level can significantly reduce the protein level of PD-L1, PD-L1 protein accumulation in tumor cells is blocked from the root of PD-L1 protein synthesis, and immune escape of the tumor cells is blocked.
Owner:ZHEJIANG UNIV
Preposed cavitation type marihuana fat-soluble active matter soluble microneedle as well as preparation method and application thereof
PendingCN114225033AReduce resistanceIncreased transdermal penetration coefficientHeavy metal active ingredientsHydroxy compound active ingredientsCannabisPharmaceutical drug
The invention relates to a preposed cavitation type hemp fat-soluble active matter soluble microneedle, which comprises a backing layer and a microneedle array fixed on the backing layer, and one of active metal particles, bicarbonate, bicarbonate, cerium dioxide particles or cerium-zirconium composite oxide particles is embedded in the tip part of the microneedle; and the needle body is filled with a soluble microneedle matrix material containing a cannabis fat-soluble active matter solid dispersion. According to the preposed cavitation type cannabis sativa active ingredient microneedle disclosed by the invention, by utilizing preposed bubbles, the delivery resistance of an embedded medicine to a tumor deep layer is greatly reduced, and the transdermal permeability coefficient is greatly improved; generated hydrogen / oxygen / carbon dioxide and the like can remarkably improve the tumor immunosuppression microenvironment and cooperate with other embedded anti-tumor drugs to improve the treatment efficiency; and the required administration dosage is greatly reduced, so that the potential toxicity is reduced, and the comprehensive treatment efficiency on various superficial skin tumors is obviously improved.
Owner:中纳科(南京)生物科技有限公司
NIR response type biomimetic membrane nano vesicle as well as construction method and application thereof
ActiveCN113559066APossess the function of efficient homology targetingGrowth inhibitionPharmaceutical non-active ingredientsEmulsion deliveryCell membraneLiposome
The invention discloses an NIR response type biomimetic membrane nano vesicle and a construction method and application thereof. The construction method comprises the following steps of S1, collecting tumor cells, and obtaining a tumor cell membrane solution through a freeze thawing method, gradient centrifugation and resuspension in sequence; S2, adopting a solvent diffusion method to obtain a thermosensitive lipid drug delivery system; and S3, mixing the tumor cell membrane solution with a thermosensitive lipid drug delivery system, and performing extruding and filtering by using a liposome extruder to obtain the NIR response type biomimetic membrane nano vesicle. The NIR response type biomimetic cell membrane nano vesicle prepared by the method provided by the invention has a tumor efficient homologous targeting function, further blocks a PD-1 / PD-L1 pathway, reverses a tumor immunosuppression state for a long time, synergistically exerts anti-tumor immune response, and inhibits growth of primary tumors and metastases.
Owner:THE UNIV OF HONG KONG SHENZHEN HOSPITAL +1
Molecule, cell expressing same, and preparation method and use thereof
ActiveCN107624119ALow miss rateIncrease lethalityPeptide/protein ingredientsMammal material medical ingredientsTransmembrane domainCytokine
Provided are a chimeric immune inhibitory checkpoint receptor molecule, a nucleic acid encoding the same, a construct, expression vector and transformed cell containing the nucleic acid, and a pharmaceutical use thereof. The chimeric immune inhibitory checkpoint receptor molecule comprises an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain and the optional transmembrane domain are corresponding domains of an immune inhibitory checkpoint receptor molecule or are genetically engineered on the basis of the corresponding domains. The intracellular domain is one or more immune activation signal domains. The transformed cell has a strong tumor-killing effect and can abrogate a tumor-immunosuppressive microenvironment, thereby strengthening an immune response in the tumor microenvironment. The transformed cell also has a self-regulation function and can alleviate side effects such as an overactive, non-specific immune response and a cytokinestorm.
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD
A kind of chimeric molecular converter of T cell signal and its use
ActiveCN103965361BImprove proliferative abilityEnhance secretory functionPeptide/protein ingredientsGenetic material ingredientsSide effectSignalling molecules
The invention relates to a single chimeric converter for a T-cell signal and application thereof, which belongs to the fields of molecular biology and immunology. Specifically speaking, the single chimeric converter is formed by connection of a polypeptide highly efficiently bonding with immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells to a transmembrane domain originated from a high-affinity receptor and an intracellular peptide fragment of a costimulatory signal molecule through a hinge structure. Out-membrane polypeptide receives a signal of the immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells and transmits the signal into a cell, a second signal of immune cells is activated through the intracellular peptide fragment of the costimulatory signal molecule, so multiplication capacity of the immune cells and the secretion function of cell factors are enhanced, and the survival time of the activated immune cells is prolonged; thus, side-effects of a tumor immunosuppression microenvironment on adoptive cell therapy effector cells are overcome.
Owner:SHANGHAI CELL THERAPY GRP CO LTD
Preparing method and application of BTLA<-/->T lymphocytes resistant to tumor immunosuppression environment
InactiveCN109136190AAttack ability activatedTo achieve the purpose of treatmentStable introduction of DNAPeptidesAbnormal tissue growthSerum free media
The invention discloses a preparing method of BTLA<- / ->T lymphocytes resistant to the tumor immunosuppression environment. The preparing method includes the steps that T lymphocytes are obtained through separation from peripheral blood of a tumor patient, BTLA is subjected to gene knockout in vitro with the CRISPR-Cas9 technology, then the obtained T lymphocytes are put into a serum-free medium and cultured, IFN-gamma, a CD3 monoclonal antibody, IL-2, IL-1alpha, IL-4, GM-CSF and Puromycin are added, the obtained T lymphocytes continue to be cultured for 10 days to 15 days, then centrifugationis carried out, and the BTLA<- / ->T lymphocytes are obtained. The preparing method of the BTLA<- / ->T lymphocytes is ingenious in design, the BTLA<- / ->T lymphocytes prepared with the method have the characteristic resistant to the tumor immunosuppression environment, and have the better tumor killing effect, the clinical effect is improved, and a novel anti-tumor and tumor treatment mean is provided.
Owner:北京中诚华科生物科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com